Healthcare Industry News: HSMN NewsFeed
News Release - October 19, 2017
Johnson & Johnson Medical GmbH to Acquire Surgical Process InstituteAcquisition strengthens surgical solutions portfolio with innovative tools designed to minimize variability in care
NORDERSTEDT, Germany, Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical GmbH today announced a definitive agreement to acquire German software company, Surgical Process Institute (SPI), a leading specialist for the standardization and digitalization of surgical workflows in the operating theatre. SPI provides innovative software solutions designed to improve patient outcomes and operating room efficiency by reducing variability in surgical procedures.
This acquisition underscores Johnson & Johnson Medical Devices Companies'* commitment to driving better patient and customer outcomes through innovative technologies. Financial terms of the transaction have not been disclosed.
"At Johnson & Johnson Medical Devices Companies, we are committed to broadening our portfolio of products and services to meet the changing needs of our customers around the world," said Sandi Peterson, Group Worldwide Chair for Johnson & Johnson**. "SPI's unique offerings have been shown to reduce surgery variability and the time spent in the operating room. These new digital tools will allow us to deliver a more comprehensive and effective solution for our customers and help them continue to improve patient care."
Every year, millions of surgeries are being performed around the world. Surgeons usually follow the exact same steps to ensure consistently good results for patients. However, successful surgery is not only dependent on surgeonīs performance, it is dependent on many steps during a procedure with diverse surgical teams that have to work seamlessly together.
SPI has developed a way of standardizing surgery by translating the whole surgical experience into a detailed, step-by-step checklist that follows best-in-class standards. This means that important safety checks are completed every time, in the same order, and all supporting processes are harmonized.
With the help of SPIīs Surgical Procedure Manager (SPM) proprietary software solution, best-in-class surgical standards can be ensured across all teams which leads, not only to a better operating room utilization and efficiency, but also to more consistent outcomes and a better patient experience.
"Our aim is to establish optimal medical standards in surgery, so that patients have access to the best treatment no matter where they are undergoing surgery," says Gunter Trojandt, Managing Director Surgical Process Institute. "We have products already in use in a significant number of larger hospitals in Germany and further projects are underway in Germany, Switzerland and the Nordic Countries."
SPIīs products will be available in EMEA via Johnson & Johnson Medical Devices Companies in 2018, pilots across all other regions will start in 2018 aiming for full worldwide product availability in 2019.
The closing of the transaction is subject to customary closing conditions. The transaction is expected to close during the fourth quarter of 2017.
Notes to editors
*About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies' purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs, and research and development capabilities in surgical technology, orthopedics, cardiovascular, and specialty solutions with an offering directed at delivering clinical and economic value to healthcare systems worldwide.
**About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products, and services to advance the health and well-being of people. Approximately 128,300 employees at more than 275 Johnson & Johnson operating companies work with partners in healthcare to touch the lives of over a billion people every day, throughout the world.
Source: Johnson & Johnson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsNew GLOBAL UNITE Reverse Fracture Shoulder Implant from DePuy Synthes Addresses Unmet Needs in Complex Shoulder Fractures
CERENOVUS Receives FDA Clearance For Next Generation Stent Retriever Device Used To Treat Ischemic Stroke
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)